Kornimate/medical-research-clean huggingface dataset:
can we use intravenous injection of tranexamic acid in routine practice with active management of the third stage of labor?

Conditions: Obstetrical Hemorrhage

Summary: obstetrical hemorrhage accounts for nearly one quarter of all maternal deaths worldwide and was the most common cause of maternal death in the turkey \[1,2\]. most of these deaths occur within 4 h of delivery and are a result of problems during third and fourth stages of labor. it also contributes significantly to serious maternal morbidity. obstetric, surgical and radiological interventions play central role in the management of obstetric hemorrhage; however, pharmacologic management and in particular prohemostatic therapies also play an important role in the final maternal outcome. administration of tranexamic acid (ta), intravenously in the third stage of labor may be one of these methods. ta a synthetic derivate of the amino acid lysine, is an antifibrinolytic that reversibly inhibits the activation of plasminogen, thus inhibiting fibrinolysis and reducing bleeding. ta may enhance the effectiveness of the patient's own hemostatic mechanism \[3,4\]. in nonobstetric surgery, a systematic review of randomized controlled trails showed that tranexamic acid reduced the risk of blood transfusion \[ relative risk (rr) 0.61; 95% ci 0.54-0.69\] and also reduced the need for re-operation as a result of bleeding (rr 0.67; 95% ci 0.41-1.09). there was no evidence for an increased risk of thrombotic events \[5\]. in gynecology and obstetrics, ta is most commonly used to treat idiopathic menorrhagia, and is an effective and well-tolerated treatment when administered orally \[5,6,7\]. bleeding associated with pregnancy (placental abruption, placenta previa) has also been treated with ta \[6\]. furthermore, four randomized controlled studies have shown that ta reduces postpartum hemorrhage (pph) following cesarean delivery \[7-11\]. only one randomized trail is available evaluating the effect of ta use to prevent bleeding in the postpartum period following spontaneous vaginal delivery \[12\]. the purpose of our study was to estimate the effect of the addition of intravenous ta to a standard active management of the third stage of labor (which includes prophylactic injection of 10 iu of oxytocin within two minutes of birth, early clamping of the umbilical cord, and controlled cord traction).


Eligibility criteria:
inclusion criteria: * gestational age between 37 and 42 weeks, * live fetus, * cephalic presentation, * vaginal birth. * patients who had a risk factors for pph, such as multiple gestation, polyhydramnios, fetal macrosomia, antepartum hemorrhage, anemia (haemoglobin concentration \< 8 g/dl), severe pre-eclampsia, or coagulopathy exclusion criteria: * placenta previa, * placental abruption, * cesarean section or any uterine scar, abnormal placentation (accreta, increta, or percreta), * a current or previous history of significant disease, including heart disease, liver, renal disorders.
study to evaluate the efficacy of tetracycline in epidermolysis bullosa

Conditions: Epidermolysis Bullosa

Summary: epidermolysis bullosa(eb) is an inherited bullous disease. tetracycline is believed to have anti inflammatory properties. 20 patients with eb older than 13 years will be treated for 4 months with tetracycline or placebo. after one month of wash out they will be treated for additional 4 m with placebo or tetracycline. the patients will be examined each month to estimate bulla formation,rate of healing .

epidermolysis bullosa(eb) is an inherited bullous disease. tetracycline is believed to have anti inflammatory properties. 20 patients with eb older than 13 years will be treated for 4 months with tetracycline or placebo. after one month of wash out they will be treated for additional 4 m with placebo or tetracycline. the patients will be examined each month to estimate bulla formation,rate of healing .

Eligibility criteria:
inclusion criteria: * diagnosed as epidermolysis bullosa * not pregnant * active disease * more than 5 bulla- exclusion criteria: * age less than 13 * known sensitivity to tetracyclin * abnormal liver and kidney tests.
cyc065 cdk inhibitor and venetoclax study in relapsed/refractory cll

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia

Summary: a phase i combination study of cyc065 and venetoclax for relapsed or refractory chronic lymphocytic leukemia (cll)

this is an open-label, single arm, dose escalation study in patients with relapsed or refractory cll. treatment will be administered on an outpatient basis and all patients will receive cyc065 over 4-hour infusion once every 2 weeks on day 1 and day 15 in combination with venetoclax. one treatment cycle is 4 weeks.

Eligibility criteria:
inclusion criteria: * cll that is relapsed or refractory to btk inhibitors and is on a stable dose of venetoclax * ecog 0-2 * adequate bone marrow function * adequate renal function * adequate liver function * inr \<=1.2 in patients not receiving chronic anticoagulation * at least 4 weeks from prior cytotoxic chemotherapy * at least 4 weeks from major surgery * agree to practice effective contraception exclusion criteria: * known cll involvement in cns that is symptomatic and active * currently receiving radiotherapy, biological therapy, or any other investigational agents * uncontrolled intercurrent illness * pregnant or lactating * known to be hiv-positive * known active hepatitis b and/or hepatitis c infection

Keywords: cyc065 cdk2/9 venetoclax bcl-2 mcl-1 relapsed refractory chronic lymphocytic leukemia small lymphocytic lymphoma
angiogenic cytokines and fibrinolytic activity in parapneumonic effusions

Conditions: Pleural Effusion

Summary: angiogenesis is a key process in the formation of exudative pleural effusions. fluid loculation is common in parapneumonic effusion and is associated with depressed pleural fibrinolytic activity and poor clinical outcome. however, the relationship between angiogenic cytokines and fibrinolytic activity in the pleural space remains unclear. the researchers's hypothesis is that the levels of angiogenic cytokines were increased and associated with decreased fibrinolytic activity in parapneumonic effusions which may contribute to fibrin deposition and fluid loculation in the pleural space.

formation of parapneumonic effusions (ppe) involves increased pleural vascular permeability induced by the contiguous pneumonia. it has been demonstrated that exposure of pleural mesothelial cells to bacteria or lipopolysaccharide (lps) leads to increased release of angiogenic factors, including vascular endothelial growth factor (vegf) and interleukin (il)-8, which induce vascular hyperpermeability, fluid exudation, and neutrophil influx into the pleural space, and may play a pivotal role in development of ppe. with persistent inflammation and angiogenesis, amplified vascular and mesothelial permeability leads to increased plasma extravasation, activation of the coagulation cascade, and repression of fibrinolytic activity within the pleural cavity, which contribute to the development of a ''complicated'' ppe, manifested with fibrin deposition and pleural fluid loculation. fibrin turnover in the pleural cavity is greatly affected by fibrinolytic activity mediated by plasmin, which is regulated mainly by the equilibrium between plasminogen activators (pas) and plasminogen activator inhibitors (pais).vegf induces vascular hyperpermeability and may facilitate the genesis of fibrin gel in ppe. previous studies reported that vegf plays a role in the modulation of tpa and pai-1, and that anti-vegf antibody attenuates pleurodesis induced by transforming growth factor-β2. these findings suggest that vegf may be involved in the regulation of fibrin turnover, fluid loculation and tissue fibrosis in the pleural space. enhanced procoagulant and depressed fibrinolytic activities have been observed in ppe. however, the relationship between angiogenic cytokines and fibrinolytic activity in ppe remains unclear.

Eligibility criteria:
inclusion criteria: * patients with pleural effusions of unknown causes admitted to taipei medical university hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the american thoracic society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph). exclusion criteria: * history of chest trauma or invasive procedures directed into the pleural cavity; bleeding disorder or anticoagulant therapy * use of streptokinase in the previous 2 years; and likely survival less than 6 months.

Keywords: pleural effusion angiogenic cytokine fibrinolytic activity
evaluation of early retinal vascular modifications after endoscopic endonasal pituitary surgery

Conditions: Pituitary Adenoma

Summary: this study evaluates the retinal vascular features using optical coherence tomography angiography in patients that received endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.

to investigate the potential role of optical coherence tomography angiography in predicting the postoperative recovery of retinal vascular network of the optic disc in patients before and at 3 months after endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve. the optical coherence tomography angiography represents a novel and non-invasive diagnostic technique that allows a detailed analysis of retinal vascular features.

Eligibility criteria:
inclusion criteria: * age older than 45 years * diagnosis of pituitary adenoma * treatment-naïve with endoscopic endonasal pituitary surgery * absence of other neurological diseases * absence of vitreoretinal and vascular retinal diseases exclusion criteria: * age younger than 45 years * no diagnosis of pituitary adenoma * previous treatments with endoscopic endonasal pituitary surgery * presence of neurological diseases * presence of vitreoretinal and vascular retinal diseases
efficacy and safety of lansoprazole on gastric and duodenal ulcers in patients taking nonsteroidal anti-inflammatory drugs

Conditions: Stomach Ulcer; Duodenal Ulcer

Summary: the purpose of this study is to determine whether ag-1749 (lansoprazole), once daily (qd), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term treatment with nonsteroid anti-inflammatory drug, compared to gefarnate, twice daily (bid).

in japan, nonsteroid anti-inflammatory drug is one of common prescribed drugs for patients as an analgesic antipyretic, treating symptoms of cold, antiphlogistic and management of pain with rheumatoid arthritis, osteoarthrosis, lumbago. on the other hand, this nonsteroid anti-inflammatory drug sometimes causes gastric and duodenal ulcers and this ulcer leads to the gastrointestinal bleeding which may be cause of death. the purpose of this study is to assess the efficacy of lansoprazole versus gefarnate in patients with a history of gastric or duodenal ulcers receiving daily nonsteroid anti-inflammatory medication.

Eligibility criteria:
inclusion criteria: * the patient was on nonsteroid anti-inflammatory drug (nsaid) treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started. * the patient was confirmed to have a history of gastric ulcer or duodenal ulcer. exclusion criteria: * endoscopically confirmed gastric and/or duodenal ulcers on day 1. * endoscopically confirmed active upper gastrointestinal hemorrhage on day 1. * current or past history of aspirin-induced asthma or hypersensitivity to nsaids. * past or planned surgery affecting gastric acid secretion. * clinically significant hepatic or renal disorder. * serious cardiac dysfunction, hypertension, or hematological disorder.

Keywords: curling ulcer gastric ulcer nonsteroid anti-inflammatory drug drug therapy
online psychological group interventions

Conditions: Depression; Anxiety

Summary: the aim is to assess the effectiveness of online group cbt for reducing symptoms of depression and anxiety among university students. the investigators will conduct a four-arm randomised control trial comparing a 10-session online group cbt intervention to three mental health apps (namely silvercloud guided, silvercloud unguided, and mood flow).

email invitations and information about the study will be sent to random samples of students inviting those with symptoms of depression, anxiety, or stress to join the trial. students who express interest will be asked to complete an online consent form (providing more detailed information about the study and explaining potential risks and benefits of participation), following which they will complete a baseline assessment. students who meet inclusion criteria will then be randomly allocated to one of four interventions. follow-up assessments will be done at 3-, 6- and 12-months post intervention. the baseline assessment will include measures of depression and anxiety, as well as factors that could potentially predict treatment responses (such as gender, age, substance use, self-harm, adverse childhood experiences, and physical health). follow-up assessments will include measures of depression and anxiety, as well as substance use, self-harm, and treatment seeking. the primary outcomes will be symptoms of depression and anxiety as measured by the gad-7 and phq-9.

Eligibility criteria:
inclusion criteria: 1. aged 18 or older years. 2. enrolled as a student at stellenbosch university. 3. provide informed consent. 4. access to internet to join the online group. exclusion criteria: 1. no internet availability. 2. did not provide informed consent

Keywords: online group psychological intervention depression anxiety online group cognitive behavioural therapy app-based interventions randomized controlled trial
hyperoxic oxidative stress during abdominal surgery

Conditions: Response to Hyperoxia

Summary: our aim is to compare the effects of 80% and 40% fraction of inspired oxygen on oxidative stress, antioxidant response (in plasma and bronchoalveolar lavage), extubation quality, preanesthetic and postanesthetic expiration tidal volumes.


Eligibility criteria:
inclusion criteria: * patients undergoing abdominal surgery, between 20-60 years old, with american society of anesthesiology score i or ii exclusion criteria: * patients with chronic obstructive pulmonary disease, diabetes mellitus, muscle-bone diseases, inflammatory bowel diseases and patients with malnutrition. patients will be recruited through general surgery service of our hospital
operative versus non operative management outcomes of isolated lateral malleolar weber b ankle fractures

Conditions: Ankle Fractures

Summary: the primary objective of this study is to determine the failure rate and difference in clinical outcomes between operative and non operative treatment of patients with weber b lateral malleolus ankle fractures with medial clear space widening on gravity stress views. all patients presenting will be treated non operatively, and compared to an observational group comprised of patients with weber b lateral malleolus ankle fractures without medial clear space widening, for which the standard of care is non operative management. patients who decline non operative management and elect to undergo operative open reduction internal fixation with plates and screws will comprise an operative observational cohort. all patients will be followed for a total of 12 months from the time of injury. clinical outcomes will be based on radiographic monitoring for ankle mortise congruency, as well as standardized sf-36 and aofas questionnaire scores.


Eligibility criteria:
inclusion criteria: * 18-65 years old * able to provide informed consent exclusion criteria: * pregnancy * prisoners * psychiatric conditions that prevent ability to provide informed consent or present barriers to follow up * insulin dependent diabetics * patients with prior musculoskeletal issues affecting the same extremity * patients cannot simultaneously be enrolled in any other studies.
vaginal biorevitalization with polydeoxyribonucleotides for the improvement of the genitourinary syndrome of menopause

Conditions: Genitourinary Syndrome of Menopause; Postmenopausal Disorder; Menopause; Vagina Atrophy

Summary: the aim of the study was to compare the efficacy of vaginal biorevitalization to improve the genitourinary syndrome of menopause (gsm) between the gold-standard treatment with local estrogen-based hormone therapy versus local salmon polydeoxyribonucleotide (pdrn) therapy.

the aim of the study was to compare the efficacy of vaginal biorevitalization to improve the genitourinary syndrome of menopause (gsm) between the gold-standard treatment with local estrogen-based hormone therapy versus local salmon polydeoxyribonucleotide (pdrn) therapy. thus, a randomized clinical trial was conducted in 136 first-time postmenopausal women with gsm, from the "peri-postmenopause and bone metabolism clinic" of the "regional hospital october 1st " of the "institute of security and social services for state workers (issste)", from june 2021 to december 2021. participants were referred by the family medicine service or by another service of the hospital. the control group (n=63) received local estrogen-based hormonal therapy, applied topically to the vagina mucosa on monday, wednesday, and friday of each week, for 3 months, while the experimental group (n=70) received local salmon pdrns on vaginal suppositories, applied solely for six days every night in the first week. then, experimental group participants were maintained without further treatment up to the control evaluation. the follow-up assessment was done after 3 months. the alterations in the urogenital domain of the mrs score (items 9-11), vaginal maturity index (vmi), vaginal ph, estrogenic effect, floor pelvic contraction capacity, as well as colposcopy findings, were the main outcomes of the study.

Eligibility criteria:
inclusion criteria: * first-time patients with the diagnosis of genitourinary syndrome of menopause with an mrs \> 5 in the urogenital domain, with alterations in the vaginal maturity index (vmi). exclusion criteria: * incomplete clinical records. * history of prolonged use of steroids. * use of alternative local therapies applied in the vagina's mucosa. * use of local therapies with vaginal suppositories for any reason 15 days before the beginning of the study. * clinical evidence of infectious cervical-vaginitis or vulvovaginitis. * evidence of urinary tract infection (uti). * lack of adherence to medical treatment. * diagnosis of cancer. * diagnosis of depression. * diagnosis of uncontrolled primary or secondary immunodeficiencies. * allergies to any of the medications administered. * birads \>2 or high risk of developing breast cancer, ovarian cancer or endometrial cancer. * use of oral hormonal or non-hormanl therapy.

Keywords: polynucleotides genitourinary syndrome of menopause postmenopause vagina atrophy vaginal biorevitalization
development, reliability and validity of the telerehabilitation satisfaction questionnaire- trsq

Conditions: Neurological Disease

Summary: parkinson's disease (pd), stroke, and multiple sclerosis (ms) are the most common neurological diseases. today, physiotherapy and rehabilitation approaches together with optimal medical and surgical treatment form the basis of treatment for these diseases. recently, it has been stated that various telerehabilitation interventions in the field of physiotherapy and rehabilitation may be an additional option to the rehabilitation approaches applied in the clinic. in addition, there are benefits such as continuity in patient education and rehabilitation, saving time and expenditure of individuals on the road. however, some problems arise in this form of treatment. especially weak internet connection, sometimes requiring technical knowledge and expensive equipment can reduce the participation and satisfaction level of individuals. it is also important to evaluate the level of satisfaction in expanding the usability of telerehabilitation services and determining the best telerehabilitation service. for this reason, there is a need for questionnaires investigating the satisfaction level of physiotherapy and rehabilitation applied through telerehabilitation.

questionnaire items were created in two stages. first, 5 experts will independently review the literature on "telerehabilitation" and "satisfaction". in addition, these experts will be asked to create a pool of questions based on their experiences in telerehabilitation and by taking the opinions of patients receiving telerehabilitation about satisfaction. then, 5 experts will come together and obtain a single question pool containing the questions they deem important in their question pool. the second step will involve scaling the elements. in this study, scale items will be scored on a five-point likert scale, ranging from 1, strongly disagree to 5, strongly agree. then, it will be applied to a pilot group of 10 people and it will be evaluated whether the items prepared by the experts are understood by the patients. in line with the expert opinion and the result of the pilot study, the final version of the scale will be decided and applied to ms, pd, and stroke patients who make up the study group. finally, the validity and reliability of the questionnaire will be calculated.

Eligibility criteria:
inclusion criteria: * voluntarily participate in research to accept * mini-mental test score more than or equal 24 * previously receiving physical therapy through telerehabilitation exclusion criteria: * any visual, hearing, and perception problems that may affect the answering the questionnaire items.

Keywords: multiple sclerosis parkinson disease stroke telerehabilitation satisfaction
magnetic resonance imaging in subjects with gouty tophi

Conditions: Hyperuricemia; Gout

Summary: the purpose of this study is to determine the reproducibility of magnetic resonance imaging (mri) in the quantitative assessment of tophus volume.

this is a multi-center, validation study of mri in the quantitative assessment of gouty tophi. subjects with palpable gouty tophi (confirmed by aspiration of the tophus) in select anatomical sites (foot, hand or elbow) will undergo pre- and post contrast mri on two occasions separated by 5 to 10 days. this study will consist of up to 4 study visits.

Eligibility criteria:
inclusion criteria: * subjects with gout and at least one tophi. exclusion criteria: * unable to undergo mri.

Keywords: gout tophus mri
a study to investigate the effects of pf00610335 on the qt/qtc interval in healthy volunteers

Conditions: Pulmonary Disease; Lung Disease; Moxifloxacin

Summary: a study to determine the cardiovascular effects of pf00610335 in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects aged 18 to 55 years * informed consent document signed by the subject or a legally acceptable representative * subjects who are willing and able to comply with the scheduled visits, treatment tests, laboratory tests, and other study procedures exclusion criteria: * evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic psychiatric, neurologic or allergic disease or clinical findings at screening * conditions possibly affecting drug absorption * 12-lead ecg demonstrating qtc \> 450ms or any other clinically significant abnormalities at screen * positive urine drug screen * hypersensitivity to moxifloxacin or pf00610335 * unwilling or unable to comply with the lifestyle guidelines in the protocol treatment with an investigational drug within 3 months or 5 half lives (whichever is longer) preceding the first dose of study medication

Keywords: qtc